Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.
While measurement of serum prostate specific antigen (PSA) is an important screening tool for prostate cancer, new biomarkers are necessary for better discrimination between presence and absence of disease. The MIL-38 monoclonal antibody is specific for the membrane glycoprotein glypican 1 (GPC-1) a...
Main Authors: | Douglas H Campbell, Maria E Lund, Aline L Nocon, Paul J Cozzi, Mark Frydenberg, Paul De Souza, Belinda Schiller, Jennifer L Beebe-Dimmer, Julie J Ruterbusch, Bradley J Walsh |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5908171?pdf=render |
Similar Items
-
Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)
by: Mei-Chun Yeh, et al.
Published: (2020-05-01) -
Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target
by: Dhanusha Sabanathan, et al.
Published: (2021-10-01) -
A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells
by: Maria E. Lund, et al.
Published: (2020-12-01) -
TDP-43 proteinopathy alters the ribosome association of multiple mRNAs including the glypican Dally-like protein (Dlp)/GPC6
by: Erik M. Lehmkuhl, et al.
Published: (2021-03-01) -
Mutation screening of two candidate genes from 13q32 in families affected with Bipolar disorder: human peptide transporter (SLC15A1) and human glypican5 (GPC5)
by: Detera-Wadleigh S, et al.
Published: (2002-10-01)